medscape.com/viewarticle/97...
I know many of you are members of Medscape and it is free to join.
If you aren't excerpt below.
NEW YORK (Reuters Health) - Inhaled flecainide shows promise for returning patients with recent-onset atrial fibrillation (AF) to sinus rhythm, a new study suggests
"Inhaled flecainide converts patients to sinus rhythm at a much lower - read 'safer' - plasma concentration compared to oral or intravenous treatments," said Dr. Crijns, a cardiologist at Maastricht University Medical Center in the Netherlands. A lower concentration of flecainide is possible via inhalation because the drug is absorbed from the lungs into the pulmonary venous system, which flows to the heart's left atrium, where atrial fibrillation often occurs."
N.B. The trial was sponsored by InCarda Therapeutics Inc., which is developing inhaled flecainide for paroxysmal AF. Several of Dr. Crijns' coauthors have financial ties to the company.
SOURCE: bit.ly/36v4XNn Circulation: Arrhythmia and Electrophysiology, online February 24, 2022.